Marketed & Pipeline Products for the

treatments of central nervous system

(CNS) disorders

Our recognition of an unmet patient need is what originally led Sunovion to conduct research and clinical programs in the broad category of CNS disorders.

For people struggling with other CNS disorders, Sunovion is actively working on treatments in still earlier stages of development. The strength of our drug discovery program reflects our long-term commitment to helping people live better in the future with difficult conditions such as anxiety disorders, pain management, and depression. We're optimistic that our discovery efforts in these areas will one day provide patients with safe and effective treatments leading to positive outcomes.

Insomnia

The success of LUNESTA^® (eszopiclone), a widely prescribed sleep aid, was the motivation for Sunovion's expanding research and development in this treatment area.

Sunovion has also discovered and is now in the process of developing a range of treatments for other serious central nervous system conditions.

Epilepsy

It's estimated that more than a million U.S. adults who experience the most common form of epileptic seizures are not adequately controlled on their current medicine. Sunovion's STEDESA^™ (eslicarbazepine acetate), was evaluated to be an adjunct treatment—to be used together with another medication—for these seizures.

Schizophrenia

Schizophrenia is a chronic, disabling and serious brain disorder that affects approximately 2.4 million American adults or 1 in 100 people. The World Health Organization ranks schizophrenia as the sixth leading cause of disability worldwide. Schizophrenia typically starts in the late teens to mid-30s and equally affects men and women and all ethnic and racial groups Schizophrenia is a chronic, disabling, and serious medical illness. Its causes are not well understood. People with schizophrenia can suffer from a wide range of symptoms, including hallucinations, delusions, disorganized thinking, lack of emotion, and the inability to make decisions, among others.

On October 28, 2010, the U.S. FDA approved Sunovion's Latuda^® (lurasidone HCl) tablets for adult patients with schizophrenia. LATUDA is available by prescription in pharmacies across the United States and Puerto Rico. For more information please visit www.LATUDA.com.